Valuation : Novacyt

Market Cap 36.69M 42.64M 34.43M 31.5M 58.79M 4.03B 59.25M 407M 159M 2.06B 160M 157M 6.63B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 38.64M 44.91M 36.26M 33.18M 61.92M 4.25B 62.41M 429M 167M 2.17B 169M 165M 6.99B EV / Sales 2026 *
1.27x
EV / Sales 2027 * 1.19x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-0.79%
1 week+7.73%
Current month+4.58%
1 month+24.10%
3 months+9.01%
6 months+37.53%
Current year+37.53%
1 week 0.48
Extreme 0.48
0.52
1 month 0.43
Extreme 0.4255
0.54
Current year 0.29
Extreme 0.293
0.97
1 year 0.29
Extreme 0.293
0.97
3 years 0.29
Extreme 0.293
1.39
5 years 0.29
Extreme 0.293
5.8
10 years 0.04
Extreme 0.0429
13.78
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%+7.73% - - 42.64M
+23.71%0.00% - - 948M
-2.64%-1.77%-37.61%-42.32% 646M
+2.85%-8.66%+72.34% - 324M
-5.92%-5.62%-36.69%-18.90% 126M
0.00%-13.04%-29.96%+20.00% 69.92M
Average +2.87%-5.67%-7.98%-13.74% 422.66M
Weighted average by Cap. +9.70%-2.70%-6.52%-33.63%

Financials

2026 *2027 *
Net sales 30.52M 35.48M 28.65M 26.21M 48.92M 3.35B 49.3M 339M 132M 1.71B 133M 130M 5.52B 34.86M 40.52M 32.71M 29.93M 55.86M 3.83B 56.31M 387M 151M 1.96B 152M 149M 6.3B
Net income - -
Net Debt 1.96M 2.27M 1.84M 1.68M 3.13M 215M 3.16M 21.71M 8.46M 110M 8.54M 8.35M 354M 4.84M 5.63M 4.54M 4.16M 7.76M 532M 7.82M 53.75M 20.93M 272M 21.13M 20.67M 876M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change
04/09/26 0.5020 -1.38%
03/09/26 €0.5090 -2.12%
02/09/26 €0.5200 +4.00%
01/09/26 €0.5000 +4.17%
31/08/26 €0.4800 +3.00%

Annual profits - Rate of surprise